Progression-Free Survival Efficacy in Refractory/Relapsed Multiple Myeloma among Elderly Patients: A Systematic Review
Background: Over the last decade, many studies have assessed the efficacy of treatments for refractory/relapsed multiple myeloma (R/R MM). While combination therapies show greater efficacy than traditional methods, limited research has targeted elderly patients who might be less resilient to treatme...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-11-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/13/12/2259 |
| _version_ | 1827574319875620864 |
|---|---|
| author | Tung-Lung Yang Chin Lin Ching-Liang Ho Tzu-Chuan Huang Yi-Ying Wu Hong-Jie Jhou Po-Huang Chen Cho-Hao Lee |
| author_facet | Tung-Lung Yang Chin Lin Ching-Liang Ho Tzu-Chuan Huang Yi-Ying Wu Hong-Jie Jhou Po-Huang Chen Cho-Hao Lee |
| author_sort | Tung-Lung Yang |
| collection | DOAJ |
| description | Background: Over the last decade, many studies have assessed the efficacy of treatments for refractory/relapsed multiple myeloma (R/R MM). While combination therapies show greater efficacy than traditional methods, limited research has targeted elderly patients who might be less resilient to treatments. Our study aimed to evaluate treatment efficacy for these elderly patients. Methods: We carried out a comprehensive review of the literature using a systematic approach. Initially, 4966 citations were retrieved and subsequently narrowed down to 13 eligible randomized controlled trials (RCTs) through our systematic review process from databases like Embase, PubMed, and Cochrane Library from 1 January 2000 to 31 December 2022. Evidence was collated through a frequentist network meta-analysis, using the hazard ratio (HR) for evaluation. Results: Combined therapy of daratumumab, lenalidomide, and dexamethasone (DaraLenDex) was the preferred treatment for R/R MM elderly patients. Its strengths included an HR for progression-free survival (0.15; 95% CI: 0.09–0.25) and a 96% P-score. Conclusions: Our analysis suggests that, pending more comprehensive RCTs, DaraLenDex is the treatment with the highest efficacy for R/R MM in elderly patients. |
| first_indexed | 2024-03-08T20:35:30Z |
| format | Article |
| id | doaj.art-172b7088250f4c6ca46c67ec5ccc7bad |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-08T20:35:30Z |
| publishDate | 2023-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-172b7088250f4c6ca46c67ec5ccc7bad2023-12-22T14:21:06ZengMDPI AGLife2075-17292023-11-011312225910.3390/life13122259Progression-Free Survival Efficacy in Refractory/Relapsed Multiple Myeloma among Elderly Patients: A Systematic ReviewTung-Lung Yang0Chin Lin1Ching-Liang Ho2Tzu-Chuan Huang3Yi-Ying Wu4Hong-Jie Jhou5Po-Huang Chen6Cho-Hao Lee7Division of Hematology and Oncology Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, TaiwanSchool of Public Health, National Defense Medical Center, Taipei 114, TaiwanDivision of Hematology and Oncology Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, TaiwanDivision of Hematology and Oncology Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, TaiwanDivision of Hematology and Oncology Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, TaiwanDepartment of Neurology, Changhua Christian Hospital, Changhua 500, TaiwanDivision of Hematology and Oncology Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, TaiwanDivision of Hematology and Oncology Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, TaiwanBackground: Over the last decade, many studies have assessed the efficacy of treatments for refractory/relapsed multiple myeloma (R/R MM). While combination therapies show greater efficacy than traditional methods, limited research has targeted elderly patients who might be less resilient to treatments. Our study aimed to evaluate treatment efficacy for these elderly patients. Methods: We carried out a comprehensive review of the literature using a systematic approach. Initially, 4966 citations were retrieved and subsequently narrowed down to 13 eligible randomized controlled trials (RCTs) through our systematic review process from databases like Embase, PubMed, and Cochrane Library from 1 January 2000 to 31 December 2022. Evidence was collated through a frequentist network meta-analysis, using the hazard ratio (HR) for evaluation. Results: Combined therapy of daratumumab, lenalidomide, and dexamethasone (DaraLenDex) was the preferred treatment for R/R MM elderly patients. Its strengths included an HR for progression-free survival (0.15; 95% CI: 0.09–0.25) and a 96% P-score. Conclusions: Our analysis suggests that, pending more comprehensive RCTs, DaraLenDex is the treatment with the highest efficacy for R/R MM in elderly patients.https://www.mdpi.com/2075-1729/13/12/2259frailelderlyrefractory and relapsed multiple myeloma |
| spellingShingle | Tung-Lung Yang Chin Lin Ching-Liang Ho Tzu-Chuan Huang Yi-Ying Wu Hong-Jie Jhou Po-Huang Chen Cho-Hao Lee Progression-Free Survival Efficacy in Refractory/Relapsed Multiple Myeloma among Elderly Patients: A Systematic Review Life frail elderly refractory and relapsed multiple myeloma |
| title | Progression-Free Survival Efficacy in Refractory/Relapsed Multiple Myeloma among Elderly Patients: A Systematic Review |
| title_full | Progression-Free Survival Efficacy in Refractory/Relapsed Multiple Myeloma among Elderly Patients: A Systematic Review |
| title_fullStr | Progression-Free Survival Efficacy in Refractory/Relapsed Multiple Myeloma among Elderly Patients: A Systematic Review |
| title_full_unstemmed | Progression-Free Survival Efficacy in Refractory/Relapsed Multiple Myeloma among Elderly Patients: A Systematic Review |
| title_short | Progression-Free Survival Efficacy in Refractory/Relapsed Multiple Myeloma among Elderly Patients: A Systematic Review |
| title_sort | progression free survival efficacy in refractory relapsed multiple myeloma among elderly patients a systematic review |
| topic | frail elderly refractory and relapsed multiple myeloma |
| url | https://www.mdpi.com/2075-1729/13/12/2259 |
| work_keys_str_mv | AT tunglungyang progressionfreesurvivalefficacyinrefractoryrelapsedmultiplemyelomaamongelderlypatientsasystematicreview AT chinlin progressionfreesurvivalefficacyinrefractoryrelapsedmultiplemyelomaamongelderlypatientsasystematicreview AT chingliangho progressionfreesurvivalefficacyinrefractoryrelapsedmultiplemyelomaamongelderlypatientsasystematicreview AT tzuchuanhuang progressionfreesurvivalefficacyinrefractoryrelapsedmultiplemyelomaamongelderlypatientsasystematicreview AT yiyingwu progressionfreesurvivalefficacyinrefractoryrelapsedmultiplemyelomaamongelderlypatientsasystematicreview AT hongjiejhou progressionfreesurvivalefficacyinrefractoryrelapsedmultiplemyelomaamongelderlypatientsasystematicreview AT pohuangchen progressionfreesurvivalefficacyinrefractoryrelapsedmultiplemyelomaamongelderlypatientsasystematicreview AT chohaolee progressionfreesurvivalefficacyinrefractoryrelapsedmultiplemyelomaamongelderlypatientsasystematicreview |